Publicaciones en colaboración con investigadores/as de University of Würzburg (85)

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma

    Communications Biology, Vol. 6, Núm. 1

  3. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 1, pp. 279-288

2022

  1. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

    Journal of the National Cancer Institute, Vol. 114, Núm. 1, pp. 109-122

  2. Consortium neuroscience of attention deficit/hyperactivity disorder and autism spectrum disorder: The ENIGMA adventure

    Human Brain Mapping, Vol. 43, Núm. 1, pp. 37-55

  3. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

    Communications biology, Vol. 5, Núm. 1, pp. 1061

  4. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

  5. Virtual Ontogeny of Cortical Growth Preceding Mental Illness

    Biological Psychiatry, Vol. 92, Núm. 4, pp. 299-313

2021

  1. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

    Nature Communications, Vol. 12, Núm. 1

  2. Cereblon enhancer methylation and IMiD resistance in multiple myeloma

    Blood, Vol. 138, Núm. 18, pp. 1721-1726

  3. Erratum: Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature communications (2021) 12 1 (1078))

    Nature communications

  4. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  5. Large between-patient variability in egfr decline before clinical trial enrollment and impact on atrasentan’s efficacy: a post hoc analysis from the SONAR trial

    Journal of the American Society of Nephrology, Vol. 32, Núm. 11, pp. 2731-2734

  6. MLIP causes recessive myopathy with rhabdomyolysis, myalgia and baseline elevated serum creatine kinase

    Brain, Vol. 144, Núm. 9, pp. 2722-2731

  7. Prevalence and early-life risk factors of school-age allergic multimorbidity: The EuroPrevall-iFAAM birth cohort

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 9, pp. 2855-2865

  8. Primary and pollen-associated hazelnut allergy in school-aged children in Germany: A birth cohort study

    Allergology International, Vol. 70, Núm. 4, pp. 463-470

  9. Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features

    Journal of the European Academy of Dermatology and Venereology, Vol. 35, Núm. 3, pp. 658-668

  10. Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders

    JAMA Psychiatry, Vol. 78, Núm. 1, pp. 47-63

2020

  1. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness

    Cancer Research, Vol. 80, Núm. 3, pp. 624-638

  2. De novo mutations identified by exome sequencing implicate rare missense variants in SLC6A1 in schizophrenia

    Nature Neuroscience, Vol. 23, Núm. 2, pp. 179-184